Gastrointestinal Management of Neurofibromatosis Type 1 (NF1)

GI Manifestations and Risk

Patients with NF1 have a 200-fold increased risk of developing gastrointestinal stromal tumors (GISTs) and require specific surveillance and management approaches for GI manifestations 1
Gastrointestinal stromal tumors (GISTs) typically present around age 50, with a 200-fold increased risk compared to the general population, and usually lack KIT or PDGFRA alterations 1, 2

The American College of Medical Genetics and Genomics recommends annual physical examination by a physician to monitor for signs of GI involvement in children and adolescents with NF1 1
No specific GI imaging surveillance is recommended in asymptomatic children and adolescents with NF1 1, 3
Adults with NF1 should follow general population age- and gender-specific health screening, including colonoscopy, as recommended by the American College of Medical Genetics and Genomics 4, 5, 6
No specific routine GI imaging surveillance is currently recommended for asymptomatic adults with NF1 1, 7

For suspected GIST, endoscopic ultrasound (EUS) with fine needle aspiration or core needle biopsy is preferred, as recommended by the British Journal of Cancer 2
Complete surgical resection is the standard treatment for localized GISTs, with segmental resection with R0 margins (complete removal with intact capsule) as the goal, according to the Cancer Treatment Reviews 8
Lymphadenectomy is generally unnecessary due to low frequency of lymph node involvement in GISTs 8
For small asymptomatic submucosal lesions <2cm, surveillance with annual EUS may be considered, as recommended by the British Journal of Cancer 2

Patients with NF1 should be evaluated by a specialized NF1 clinic when possible, with involvement of gastroenterologists in the multidisciplinary team for patients with GI manifestations, as recommended by the Genetics in Medicine and Gut 4, 6, 9
Genetic counseling is recommended for patients with NF1 and GI tumors, as well as their relatives, according to the Cancer Treatment Reviews 8
NF1 patients are at increased risk for other cancers, so new unexplained symptoms should prompt investigations for other GI cancers, as recommended by the Gut 9